The latest price target for Ampio Pharmaceuticals (OTCEM:AMPE) was reported by Alliance Global Partners on March 24, 2022. The analyst firm set a price target for $4.50 expecting AMPE to rise to within 12 months (a possible 5892.01% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Ampio Pharmaceuticals (OTCEM:AMPE) was provided by Alliance Global Partners, and Ampio Pharmaceuticals initiated their buy rating.

There is no last upgrade for Ampio Pharmaceuticals

There is no last downgrade for Ampio Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ampio Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ampio Pharmaceuticals was filed on March 24, 2022 so you should expect the next rating to be made available sometime around March 24, 2023.

While ratings are subjective and will change, the latest Ampio Pharmaceuticals (AMPE) rating was a initiated with a price target of $0.00 to $4.50. The current price Ampio Pharmaceuticals (AMPE) is trading at is $0.08, which is within the analyst’s predicted range.